Unknown

Dataset Information

0

Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity.


ABSTRACT: Studies of interleukin (IL)-33 reveal a number of pleiotropic properties. Here, we report that IL-33 has immunoadjuvant effects in a human papilloma virus (HPV)-associated model for cancer immunotherapy where cell-mediated immunity is critical for protection. Two biologically active isoforms of IL-33 exist that are full-length or mature, but the ability of either isoform to function as a vaccine adjuvant that influences CD4 T helper 1 or CD8 T-cell immune responses is not defined. We showed that both IL-33 isoforms are capable of enhancing potent antigen-specific effector and memory T-cell immunity in vivo in a DNA vaccine setting. In addition, although both IL-33 isoforms drove robust IFN-? responses, neither elevated secretion of IL-4 or immunoglobulin E levels. Further, both isoforms augmented vaccine-induced antigen-specific polyfunctional CD4(+) and CD8(+) T-cell responses, with a large proportion of CD8(+) T cells undergoing plurifunctional cytolytic degranulation. Therapeutic studies indicated that vaccination with either IL-33 isoform in conjunction with an HPV DNA vaccine caused rapid and complete regressions in vivo. Moreover, IL-33 could expand the magnitude of antigen-specific CD8(+) T-cell responses and elicit effector-memory CD8(+) T cells. Taken together, our results support the development of these IL-33 isoforms as immunoadjuvants in vaccinations against pathogens, including in the context of antitumor immunotherapy.

SUBMITTER: Villarreal DO 

PROVIDER: S-EPMC4130175 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity.

Villarreal Daniel O DO   Wise Megan C MC   Walters Jewell N JN   Reuschel Emma L EL   Choi Min Joung MJ   Obeng-Adjei Nyamekye N   Yan Jian J   Morrow Matthew P MP   Weiner David B DB  

Cancer research 20140121 6


Studies of interleukin (IL)-33 reveal a number of pleiotropic properties. Here, we report that IL-33 has immunoadjuvant effects in a human papilloma virus (HPV)-associated model for cancer immunotherapy where cell-mediated immunity is critical for protection. Two biologically active isoforms of IL-33 exist that are full-length or mature, but the ability of either isoform to function as a vaccine adjuvant that influences CD4 T helper 1 or CD8 T-cell immune responses is not defined. We showed that  ...[more]

Similar Datasets

| S-EPMC4635936 | biostudies-literature
| S-EPMC4817913 | biostudies-literature
| S-EPMC6309998 | biostudies-literature
| S-EPMC4579851 | biostudies-literature
| S-EPMC5875946 | biostudies-literature
| S-EPMC4339042 | biostudies-literature
| S-EPMC2981473 | biostudies-literature
| S-EPMC2678417 | biostudies-literature
| S-EPMC7578377 | biostudies-literature
| S-EPMC11010340 | biostudies-literature